Glioblastoma (GBM) is the most common primary brain tumor in adults and often has amplification of the epidermal growth factor receptor (EGFR) gene. The value of EGFR as a prognostic marker in GBMs is unclear; some studies have shown an adverse correlation, whereas others have indicated a neutral or even favorable association with longer survival. Furthermore, EGFR-amplified GBMs are usually regarded as a single subgroup of tumors, although the range of EGFR copy number varies greatly. In this study, 532 GBMs were analyzed for EGFR amplification via fluorescence in situ hybridization at the time of initial diagnosis. Although there was no difference in survival by EGFR amplification (P = 0.33), stratification by the amount of EGFR amplification showed that, surprisingly, median survival was 39% longer in the high-amplifier group (EGFR:chromosome 7 ratio >20) compared to nonamplified GBMs (P = 0.03) and was 43% longer compared to GBMs with low to moderate EGFR amplification (EGFR:chromosome 7 ratio = 2 to 20; P = 0.0007). Stratifying by postsurgical treatment regimens, this difference was seen only when temozolomide (TMZ) was used; tumors without amplification and with high EGFR amplification both responded better to TMZ than those with low to moderate amplification (P = 0.01), whereas GBMs that had not been treated with adjuvant therapy nor with adjuvant therapy lacking TMZ showed no survival differences (P = 0.63 and 0.91, respectively). These results suggest that GBMs with EGFR amplification are a heterogenous group of tumors and that behavior might differ according to the degree of amplification, although not in a straightforward dose-response manner.
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Key Words: EGFR, amplification, temozolomide, glioblastoma (Am J Surg Pathol 2012;36:1186-1193) E pidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase on chromosome 7p12 whose downstream signaling pathways modulate a wide range of cellular activities, including growth, migration, and survival. 22 As EGFR is a powerful oncogene, it is not surprising that neoplasms have developed multiple ways of enhancing its activity. Such strategies include upregulation of EGFR protein expression, inhibition/deletion of downstream pathway inhibitors, constitutively active EGFR (EGFRvIII), and EGFR amplification, 1, 30 the latter producing an excess of EGFR genes in the tumor cell.
Amplification of EGFR (or other receptor tyrosine kinases) is a frequent event in many cancers, including those of the lung, breast, head and neck, gastrointestinal tract, and brain. In the brain, EGFR amplification is a hallmark of glioblastoma (GBM), the most common and lethal primary brain tumor in the adult population. [23] [24] [25] About 40% of all GBMs have EGFR amplification, specifically those that arise de novo as GBMs. In contrast, GBMs that develop from lower-grade gliomas are much less likely to have EGFR amplification. 4, [23] [24] [25] In GBMs, EGFR signaling promotes cell division, tumor invasiveness, and resistance to radiation and chemotherapy. 7, 10, 16, 20 Considerable effort has thus been invested in developing targeted anti-EGFR therapies, with limited success so far. 6, 21, 28 Furthermore, multiple reports on the value of EGFR amplification as a prognostic marker have yielded conflicting results, with some studies showing no association with survival, others with negative impact, and some even suggesting a favorable impact on patient survival. 2, 3, 13, 14, 17, 29, 30 In such EGFR-based studies, the cutoff for amplification is generally at 2 or more copies of EGFR per copy of chromosome 7. Such a determination is usually made through fluorescence in situ hybridization (FISH), which uses fluorophore-labeled DNA probes to determine EGFR copy number and chromosome 7 ploidy. Yet an EGFR:chromosome 7 ratio of 2 or more encompasses a wide range of ratios, all of which are routinely pooled together when studying EGFR-amplified gliomas.
Herein we describe a cohort of 532 GBMs, all of which had been analyzed by EGFR FISH at the time of initial diagnosis. Our results suggest that GBM behavior and response to therapy differ according to the degree of EGFR amplification, although not in a linear manner.
MATERIALS AND METHODS

Cohort
Biopsy materials from 532 gliomas from patients aged 18 to 89 years were analyzed at the time of diagnosis for EGFR amplification at the University of Pittsburgh Medical Center from 2002 to 2010. In many biopsy samples EGFR expression, MGMT promoter methylation, and 10q loss of heterozygosity (LOH) analyses had also been done (see below). Cases of recurrent or treated gliomas were excluded. Diagnoses were rendered according to standard World Health Organization (WHO) criteria. 19 Clinical variables, including survival from the time of initial surgery, were obtained from the University of Pittsburgh Hillman Cancer Registry. All outcomebased analyses were performed according to the University of Kentucky and University of Pittsburgh Institutional Review Board guidelines.
Fluorescence In Situ Hybridization
FISH for EGFR was performed as previously described. 11 Briefly, 5-mm sections from formalin-fixed, paraffin-embedded (FFPE) tissues were deparaffinized twice in xylene for 10 minutes, dehydrated twice with 100% ethanol, and then pretreated using the Vysis Paraffin Pretreatment Kit (Abbott Molecular, Des Plaines, IL). Slides were digested for 18 minutes in protease solution (0.5 mg/mL) at 371C. FISH was performed using probes for EGFR (7p12)/centromeric enumeration probe for chromosome 7 (CEP7) (Abbott Molecular). The target slide and probe were codenatured at 951C for 8 minutes and incubated overnight at 371C in a humidified chamber. Posthybridization washes were carried out using 2XSSC/0.3% Igepal (Sigma, St Louis, MO) at 721C for 2 minutes. Slides were air-dried in the dark and counterstained with 4 0 ,6-diamidino-2-phenylindole (Abbott). Analysis was carried out using a Nikon Optiphot-2 (Nikon Inc., Melville, NY) and a Quips Genetic Workstation equipped with a Chroma Technology filter set with single-band excitors for SpectrumOrange, fluorescein isothiocyanate, and 4 0 ,6-diamidino-2-phenylindole (UV 360 nm). In each case a minimum of 60 tumor cells were scored; EGFR amplification was defined as EGFR: CEP7 ratio Z2.0.
MGMT Promoter Methylation Assay
DNA from FFPE tissues was converted using a sodium bisulfate reaction (EpiTect Bisulfite Kit, Qiagen, Valencia, CA). Real-time quantitative polymerase chain reaction (PCR) was carried out using bisulfite-specific primers for MGMT and COL2A1 (internal control) using an ABI 7900 instrument (Applied Biosystems, Carlsbad, CA). Methylation index (MI) was reported as previously described 31 ; tumors were considered negative for methylation when the MI was 0, low when MI was between 0 and 4, and high when MI was >4. In addition, methylation-specific PCR, followed by agarose gel electrophoresis, was performed as previously described with minor modifications 31 to confirm the presence or absence of methylated products.
10q LOH Analysis
PCR-based LOH analysis on 10q was performed as previously described. 11 DNA was isolated from FFPE tissues, and PCR was carried out on 2 microsatellite markers on 10q23 (D10S520 and D10S1173). PCR products were analyzed using capillary gel electrophoresis on GeneMapper ABI 3730 (Foster City, CA). Peak height ratios falling outside of 2 SDs beyond the mean of previously validated normal values were assessed as showing LOH. In the present study, LOH on either or both markers was scored as "positive" for 10q LOH.
EGFR Immunohistochemistry
EGFR immunohistochemistry was performed on FFPE tissue sections using an EGFR primary antibody (Ventana 790-2988/3C6/prediluted). Antibody labeling was carried out using the avidin-biotin complex method and was visualized with a horseradish peroxidase enzyme label and 2 0 -diaminobenzamide (Dako, Carpinteria, CA) as the substrate chromogen (brown).
EGFR immunohistochemistry analysis was based on a semiquantitative scale of 0 (negative), 1 (weak), 2 (moderate), and 3 (strong), as per our previously published results, which showed a direct correlation between this scale and the likelihood of EGFR amplification. 12 The score was predicated on the strongest area of the tumor.
The Cancer Genome Atlas Data
Affymetrix Genome-Wide Human single nucleotide polymorphism (SNP) Array 6.0 EGFR, LANCL2, and ECOP copy number data on 372 GBMs were downloaded from The Cancer Genome Atlas (TCGA) Data Portal (http://tcga-portal.nci.nih.gov/tcga-portal/Anomaly Search.jsp). A gene was considered amplified when the normalized log 2 ratio was Z1.0. Protected survival information was downloaded from the TCGA website after obtaining National Cancer Institute approval.
Statistical Analyses
Survival rates were compared using log-rank tests on Kaplan-Meier curves. The optimal survival-based cutoff between the degrees of EGFR amplification was determined by log-rank testing ( Fig. 1 ); this analysis showed an optimal EGFR:CEP7 ratio cutoff at 21.0. However, because there was no substantial difference between 21.0 and 20.0, the latter was adopted for the sake of simplicity. This also corroborated our long-standing experiential observation that FISH ratio scores become less precise once the ratio exceeds 20.
Comparisons between EGFR amplification subgroups or EGFR expression categories were made using the Kruskal-Wallis test with the Dunn post hoc test.
Correlation between patient age and EGFR:CEP7 ratio, or between EGFR amplification and WHO grade, was assessed via linear regression. Multivariate Cox proportional hazard regression was used to model survival. All the aforementioned analyses were carried out using GraphPad software (GraphPad Software Inc., La Jolla, CA) and R statistical software (survival package) (http:// www.R-project.org); differences were considered significant if P < 0.05.
RESULTS
Cohort Characteristics
A total of 532 cases were prospectively analyzed, including 221 women and 311 men, with a median age of 63 years (range: 18 to 89 y). Of them, 452 patients (85.0%) had died by the time of analysis, with a median survival of 6.8 months (range: 0.1 to 75.7 mo). Of the 80 still alive at the time of analysis, median follow-up interval was 19.1 months (range: 8.1 to 74.6 mo). Tumor location (but not laterality) was known for 484 GBMs: 143 (26.9%) were in the frontal lobe; 133 (27.5%) were in the temporal lobe; 85 (17.6%) were in the parietal lobe; 17 (3.5%) were in the occipital lobe; 59 (12.2%) were in multiple lobes; 37 (7.6%) were in deep-seated regions of the cerebrum (eg, basal ganglia, thalamus); 4 (0.8%) were in the brainstem; 3 (0.6%) were in the cerebellum; and 3 (0.6%) were in the ventricular system.
Of the 495 cases in which the type of surgery was known, 342 (69.1%) had undergone gross total or subtotal tumor resection, whereas 153 (30.9%) had been only biopsied. Postoperative treatment data were obtained for 465 patients (87.4%): 218 (46.9%) had received temozolomide (TMZ) and radiation therapy (RT); 87 (18.7%) had received TMZ, RT, and some other chemotherapy (eg, carmustine); 54 (11.6%) had received RT alone; 16 (3.4%) had received RT plus non-TMZ chemotherapy; 7 (1.5%) had received TMZ alone; 2 (0.4%) had received only non-TMZ chemotherapy; and 81 (17.4%) had received no adjuvant therapy.
Survival According to Key Clinical and Molecular Factors in GBMs
As expected, younger patients had significantly longer survival, as did patients undergoing tumor resection compared with those who had only been biopsied ( Table 1) . With regard to adjuvant therapy, the best median survival was 12.7 months in patients whose tumors had been treated with TMZ (69% in conjunction with RT; 27.9% in conjunction with RT and other chemotherapy; 2.2% by TMZ alone). Those who had undergone adjuvant therapy without TMZ (75% RT alone; 22.2% RT plus other chemotherapy; 2.8% chemotherapy alone) had the next best median survival at 6.7 months, followed by those who had received no adjuvant therapy (2.0 mo).
Factors showing no significant survival differences on univariate analyses included sex, 10q status, EGFR amplification, and EGFR expression ( Table 1) . No significant difference was seen in TMZ-treated GBMs by MGMT promoter methylation status (Supplemental Fig. 1 , http://links.lww.com/PAS/A113), although the total N for this subset was only 106 cases.
Stratification According to EGFR:CEP7 Ratio Alters Prognosis in EGFR-amplified GBMs
FISH produces EGFR copy number results in the form of a ratio, using CEP7 as a ploidy control. To determine whether GBMs with differing EGFR:CEP7 ratios also showed different behaviors, Kaplan-Meier survival curves were compared by grouping cases into 3 EGFR: CEP7 ratio bins (see the Materials and methods section and Fig. 1 ). The 3 subgroups included 301 cases (56.6%) without amplification (EGFR:CEP7 < 2); 71 tumors (13.3%) with low to moderate levels of amplification (EGFR:CEP7 = 2 to 20); and 160 (30.0%) with high-level amplification (EGFR:CEP7 > 20) ( Figs. 2A-C) . Remarkably, GBMs with high-level amplification had a median survival of 11.0 months, compared with 7.9 months for nonamplified GBMs and 7.7 months for low to moderate amplifiers (P = 0.006) (Fig. 2D) . In other words, median survival was 39% longer in the high-amplifier group compared with nonamplified GBMs (P = 0.03) and 43% longer compared with low to moderately amplified GBMs (P = 0.0007). This plot displays results from a log-rank test comparing the survival curves of patients with EGFR ratios below the cutoff with those above it. The x-axis varies cutoff values and the y-axis shows the P-value from the resulting log-rank test. The vertical black line denotes the EGFR ratio cutoff with the minimum P-value, that is, maximal separation between the 2 groups, equating to an optimal cutoff of 21.0 (for the sake of simplicity a cutoff of 20, which generated comparable P-value, was used).
EGFR Amplification Subgroups According to Key Clinical and Molecular Variables
Among the 3 EGFR subgroups (not amplified, low to moderate amplification, and high amplification) there was no significant difference in patient age, sex, or surgery type ( Table 2 ). The proportion of nonamplified, low to moderate, and high-amplified tumors also did not vary significantly by primary tumor location (P = 0.24, 0.44, and 0.21, respectively). Nonamplified GBMs had significantly lower EGFR expression compared with the amplified subgroups and a significantly lower rate of 10q LOH compared with highamplifiers. Interestingly, there was also a significant difference in the treatment groups between nonamplified and high-amplified GBMs, wherein the former had a higher rate of not having undergone adjuvant therapy, whereas the latter had a higher rate of TMZ treatment. In contrast, none of the variables significantly differed between the low to moderate amplifiers and high amplifiers. There was also no significant difference between nonamplified GBMs and low to moderately amplified GBMs according to treatment or 10q LOH. In the subset with MGMT promoter methylation data, there was no difference in methylation frequency between the EGFR subgroups.
Response to TMZ Differs According to the Degree of EGFR Amplification
Patient survival was stratified according to 3 main postsurgical treatment subsets: those who had received TMZ as part of the adjuvant therapeutic regimen; those who had received adjuvant therapies without TMZ; and patients who had received no adjuvant therapy at all (Table 1) . Survival was equally poor among the 3 EGFR subgroups when no adjuvant therapy was implemented; median survival was 2.3 months in nonamplified GBMs (N = 56), 1.9 months in low to moderately amplified tumors (N = 9), and 1.1 months in tumors with high EGFR amplification (N = 17) (overall P = 0.63, Fig. 3A) .
Compared with untreated cases, patients exposed to adjuvant therapy but without TMZ showed longer median survivals in all 3 EGFR subsets (6.0 mo for nonamplified tumors, N = 43; 7.3 mo for low to moderate amplification, N = 9; 6.7 mo for high amplifiers, N = 19), but again there were no significant differences between the subgroups (P = 0.91; Fig. 3B ).
Most cases in the cohort included TMZ as part of the postsurgical therapy. Under such treatment conditions, longer median survival was seen in both nonamplified GBMs (12.7 mo, N = 162) and high-amplified GBMs (15.3 mo, N = 110) compared with GBMs with low to moderate amplification (9.1 mo, N = 40) (overall P = 0.01; Fig. 3C) . The difference between the nonamplified and high-amplified groups was not significant (P = 0.35). In the low to moderate EGFR-amplified GBMs, median survival was only 25% higher in the TMZ-treated cases compared with those not treated with TMZ, and this difference was not significant (P = 0.55). In contrast, nonamplified GBMs treated with TMZ had a 2.1-fold longer median survival compared with nonamplified tumors that had not been treated with TMZ (P < 0.0001); similarly, high amplifiers had a 2.3-fold longer median survival than did high amplifiers without TMZ (P = 0.003).
Multivariate Analyses
All variables that were significant on univariate analyses (Table 1) were also shown to be independent prognostic factors ( Table 3 ). The presence of low to moderate EGFR amplification was also found to be an independent adverse prognostic variable (hazard ratio= 1.42; 95% confidence interval, 1.07-1.89; P = 0.017). This association was persistent in the subset of cases that were treated with TMZ (hazard ratio = 1.56; 95% confidence interval, 1.10-2.22; P = 0.013). Neither the presence of high-level EGFR amplification (hazard ratio = 0.85; P = 0.15) nor the absence of amplification (hazard ratio = 0.99; P = 0.91) was an independent prognostic marker in similar models (not shown).
DISCUSSION
EGFR is associated with WHO grade IV GBMs and is well studied, yet our understanding of the mechanisms of amplification and its impact on tumor cell biology is incomplete. Originally, it was anticipated that higher levels of EGFR amplification in this cohort might correlate with the worst outcomes. However, the relationship between EGFR amplification and outcome was paradoxical, such that lower levels of amplification correlated with worse response to TMZ-containing adjuvant therapeutic regimens compared with GBMs with high amplification or none at all. As amplification of EGFR and other receptor tyrosine kinases is seen in a variety of cancers, this phenomenon may apply to a broader range of neoplasms beyond the brain. These results may help explain the incongruities seen in other studies evaluating EGFR amplification as a glioma biomarker. Some have shown EGFR amplification to be a negative prognostic marker in GBMs, 14, 29, 30 but others have not 3, 15, 17 ; some have even suggested that it could be a favorable marker, especially in older patients. 2, 13, 29 In our large cohort, pooling all EGFR-amplified GBMs together and comparing them with nonamplified GBMs showed no difference in survival (Table 1) . It was only when the EGFR-amplified tumors were stratified according to degree of amplification that significant survival differences were unmasked (Fig. 2) . Further unmasking was carried out by subgroup analyses according to postsurgical adjuvant therapy, which suggested that there was a survival difference only if TMZ was part of the regimen and that low to moderately amplified GBMs did not respond as well to TMZ (Fig. 3 ). Thus, it is possible that the discrepancies among previous cohorts may have been due to varying proportions of these subgroups of EGFR-amplified GBMs. As only 16 cases in the entire cohort were treated with other chemotherapies but without any TMZ, it was difficult to determine whether the adverse effects of low to moderate EGFR amplification might be exclusive to TMZ or also be a feature of other chemotherapies. Nevertheless, low to moderate EGFR amplification was an independent adverse prognostic factor in a model with TMZ versus no TMZ, as well as in a model focusing only on TMZ-treated cases ( Table 3) .
The significantly better survival seen in GBMs with high EGFR amplification compared with nonamplified tumors (Fig. 2 ) may have been due to nonrandom enrichment of the latter group with GBMs not exposed to adjuvant treatment, with a concomitant reduction in the relative proportion of nonamplified cases treated with TMZ ( Table 2 ). The reason for this is not clear, as 94% of all cases were obtained from 2005 and later when TMZ was standard-of-care in GBM treatment. When reasons for withholding TMZ were retrievable, the most common were adverse systemic reactions, poor overall patient health, voluntary patient/family decisions, and inability to cover treatment costs. None of these intuitively correlated with the presence or degree of EGFR amplification. Therefore, our data as a whole suggest that high EGFR amplification might not be a favorable marker per se, but rather that low to moderate amplification is an adverse marker, especially in TMZ-treated cases. Other well-known biomarkers of GBM outcome appeared to be evenly distributed between nonamplified, low to moderate, and high-amplified GBMs. Although advanced patient age is a powerful adverse prognostic marker, 24 there was no difference in patient age, sex, or surgery between nonamplified, low to moderate, and high-level EGFR-amplified GBMs ( Table 2 ). As expected, EGFR expression and frequency of 10q LOH were higher in amplified tumors compared with nonamplified tumors, FIGURE 3 . Response to TMZ differs according to the degree of EGFR amplification. A, OS was equally poor in all 3 subgroups when no postsurgical adjuvant therapy had been administered (P = 0.63). B, Similarly, survival did not differ when adjuvant therapy was given but did not include TMZ (P = 0.91). C, However, when TMZ was part of the adjuvant regimen, patients whose GBMs had low to moderate EGFR amplification had worse survival compared with nonamplified GBMs (P = 0.02) and GBMs with high EGFR amplification (P = 0.003). OS indicates overall survival.
but there was no significant difference between the low to moderate and high-amplifier subsets with respect to any of the measured parameters. MGMT promoter methylation showed no significant difference between amplification subtypes (Table 2) ; therefore, although the number and follow-up interval of methylation-tested cases were not powerful enough for univariate and multivariate survival analyses, it is unlikely to be a confounding variable.
While our understanding of gene amplification is rudimentary, some mechanistic insights have been discovered that allow for testable hypotheses. It was demonstrated recently that, of GBMs with EGFR amplification, those with lower EGFR copy numbers tended to feature interstitial amplification, wherein all the EGFR genes were located exclusively within chromosome 7. In contrast, EGFR genes in GBMs with higher copy numbers were mostly located in fragments of extrachromosomal DNA called double minutes. 18 Double minutes have been known to exist in a variety of cancers, arising through defects in DNA reproduction and faulty repair machinery. 9, 32 Perhaps GBMs with high levels of EGFR simply have more fragile genomes, thus responding better to DNA-damaging TMZ and offsetting the otherwise deleterious effects of EGFR amplification. Indeed, other recent work has suggested that high chromosomal fragility can actually be a favorable prognostic marker in various carcinomas 5 and even in other brain tumors such as ependymomas. 33 As the size of the 7p12 amplicon varies, other nearby genes are often coamplified with EGFR and could impact tumor biology. LANCL2, for example, is coamplified and overexpressed in about 50% of EGFR-amplified GBMs. 8 LANCL2 encodes lanthionine synthetase Clike 2, which may promote sensitivity to chemotherapy. 26 About one third of EGFR-amplified GBMs also coamplify ECOP, encoding EGFR-coamplified and overexpressed protein, which upregulates the antiapoptotic activity of NF-kB. 27 The FISH probe used in this cohort for clinical testing covers the entire EGFR gene and extends beyond its 3 0 centromeric end but does not reach LANCL2 or ECOP (Supplemental Fig. 2 , http: //links.lww.com/PAS/A114). However, analysis of TCGA GBMs showed no difference in survival by coamplification of LANCL2 (Supplemental Fig. 3 , http: //links.lww.com/PAS/A115) or by coamplification of ECOP (P = 0.61, not shown).
Studying additional retrospective cohorts will be of considerable interest given the nature of these findings. Analysis of TCGA GBMs trended weakly toward a similar paradoxical relationship between the degree of amplification and outcome (Supplemental Fig. 4 , http:// links.lww.com/PAS/A116), although there are several possible reasons why a stronger relationship was not found. First, the TCGA cohort is 30% smaller than the current study. Second, the TCGA data set is inherently biased toward cases in which large resections of highly viable tumors were possible. This cohort, in contrast, studied all cases regardless of sample size and degree of necrosis, as long as at least 60 scoreable tumor cells were in the specimen. Third, copy number in the TCGA was determined by SNP arrays and reported as log 2 ratios (see the Materials and methods section). Although in principle this is analogous to FISH, in reality it proved very difficult to precisely extrapolate the FISH cutoffs to SNP array data. Nevertheless, the TCGA cohort at least suggests that the current cohort data are valid.
This study has the key advantages of a very large cohort and the prospective nature of the molecular data. Yet the survival analysis was retrospective, with all the attendant limitations thereof. Specifically, the correlation between low to moderate EGFR amplification and poorer TMZ response should be validated prospectively and could readily be incorporated into any number of ongoing clinical trials. Nevertheless, this study provides the first large-scale evidence that the degree of EGFR amplification may impact the biological behavior of GBMs, although in a counterintuitive manner. This could account for conflicting results in prior outcome-based studies of EGFR amplification and suggests that there might be more biologically relevant heterogeneity in EGFR-amplified tumors than has been previously assumed.
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